Amber Specialty Pharmacy Will Begin Dispensing TZIELD™

Amber Specialty Pharmacy announced that it will begin dispensing TZIELD™ (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D.

Indication for individuals ages 8 years and older with Stage 2 T1D is categorized by the presence of two or more T1D-related autoantibodies and abnormal blood sugars. TZIELD™ is manufactured by Provention Bio, Inc.

Amber Specialty Pharmacy’s high touch, infusion-focused service model is designed to support provider offices and appropriate patients with Stage 2 T1D across the country who may be prescribed teplizumab. The specialty pharmacy has 19 locations ready to care for these patients with their comprehensive services as well as ambulatory and home infusion capabilities.

Earlier this year, Amber Specialty Pharmacy announced that they would begin dispensing 13 Pfizer oncology products. The pharmacy’s comprehensive service model will support patients, caregivers, and oncology specialists throughout the country. Their Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey.

Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with nearly 25 years of experience providing specialized care for persons with chronic, complex medical conditions.


Takeaway: Amber Specialty Pharmacy continues to focus on providing personal and individualized care for the most vulnerable patient populations